{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:06:20Z","timestamp":1789092380768,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.coi.2026.102839","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:48:38Z","timestamp":1789087718000},"page":"102839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Complement inhibition in pediatric ANCA-associated vasculitis"],"prefix":"10.1016","volume":"103","author":[{"given":"Provini","family":"Chiara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoia","family":"Francesca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mastrangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossano","family":"Martina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di Stasio","family":"Fabiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beretta","family":"Gisella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanni","family":"Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"La Bella","family":"Saverio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filocamo","family":"Giovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vianello","family":"Federica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102839_sbref1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/BOR.0000000000001033","article-title":"Update on antineutrophil cytoplasmic autoantibody vasculitis in children","volume":"36","author":"Bloom","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.coi.2026.102839_bib2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102839_bib3","doi-asserted-by":"crossref","first-page":"13704","DOI":"10.3390\/ijms252413704","article-title":"Childhood-onset ANCA-associated vasculitis: from genetic studies to advances in pathogenesis, classification and novel therapeutic approaches","volume":"25","author":"Yeo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2026.102839_bib4","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00467-022-05855-0","article-title":"Pediatric ANCA vasculitis: clinical presentation, treatment, and outcomes in a French retrospective study","volume":"38","author":"Mahi","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.coi.2026.102839_bib5","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/acr.24590","article-title":"Consensus treatment plans for severe pediatric antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"74","author":"Morishita","year":"2022","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coi.2026.102839_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12969-017-0191-z","article-title":"Clinical practice variation and need for pediatric-specific treatment guidelines among rheumatologists caring for children with ANCA-associated vasculitis: an international clinician survey","volume":"15","author":"Westwell-Roper","year":"2017","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.coi.2026.102839_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/MOP.0000000000001102","article-title":"Antineutrophilic cytoplasmic antibody-associated vasculitis and the kidney","volume":"34","author":"Balani","year":"2022","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.coi.2026.102839_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102424","article-title":"Complement alternative pathway in ANCA-associated vasculitis: two decades from bench to bedside","volume":"19","author":"Brilland","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2026.102839_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/1744666X.2024.2405170","article-title":"Complement as a major mediator of ANCA vasculitis and a target for precision therapy","volume":"21","author":"Bunch","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.coi.2026.102839_bib10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrneph.2017.37","article-title":"Complement in ANCA-associated vasculitis: mechanisms and implications for management","volume":"13","author":"Chen","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.coi.2026.102839_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.926044","article-title":"The complement system and ANCA associated vasculitis in the era of anti-complement drugs","volume":"13","author":"Kimoto","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102839_bib12","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1681\/ASN.2005101048","article-title":"Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies","volume":"17","author":"Jennette","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.coi.2026.102839_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.semnephrol.2013.08.006","article-title":"Complement in ANCA-associated vasculitis","volume":"33","author":"Charles Jennette","year":"2013","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.coi.2026.102839_bib14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coi.2026.102839_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/BOR.0000000000000914","article-title":"The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target","volume":"35","author":"Mazzariol","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.coi.2026.102839_bib16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.autrev.2017.11.014","article-title":"Childhood- versus adult-onset ANCA-associated vasculitides: a nested, matched case\u2013control study from the French Vasculitis Study Group Registry","volume":"17","author":"Iudici","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2026.102839_bib17","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/art.42423","article-title":"Association between HLA \u2013 DPB1 and antineutrophil cytoplasmic antibody\u2013associated vasculitis in children","volume":"75","author":"Gibson","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102839_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41584-018-0145-y","article-title":"Pathogenesis and therapeutic interventions for ANCA-associated vasculitis","volume":"15","author":"Nakazawa","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2026.102839_bib19","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1002\/art.34619","article-title":"Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"64","author":"Nakazawa","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102839_sbref20","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.70338","article-title":"The complement system in ANCA-associated vasculitis: mechanistic insights, therapeutic horizons, and unmet clinical needs","volume":"14","author":"Sunmboye","year":"2026","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.coi.2026.102839_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000442323","article-title":"Overview of the pathogenesis of ANCA-associated vasculitis","volume":"1","author":"Xiao","year":"2015","journal-title":"Kidney Dis"},{"key":"10.1016\/j.coi.2026.102839_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-016-0523-y","article-title":"Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis","volume":"11","author":"Iudici","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.coi.2026.102839_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102618","article-title":"2020 international consensus on ANCA testing beyond systemic vasculitis","volume":"19","author":"Moiseev","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2026.102839_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102759","article-title":"The biology, pathogenetic role, clinical implications, and open issues of serum anti-neutrophil cytoplasmic antibodies","volume":"20","author":"Ramponi","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2026.102839_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202451721","article-title":"Current and emerging autoantibodies in ulcerative colitis","volume":"55","author":"Mendieta-Escalante","year":"2025","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coi.2026.102839_sbref26","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 Clinical Practice Guideline for the management of antineutrophil cytoplasmic antibody (ANCA)\u2013associated vasculitis","volume":"105","author":"Floege","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.coi.2026.102839_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/br.2025.1956","article-title":"Diagnosis and latest treatment strategies of ANCA\u2011associated glomerulonephritis (Review)","volume":"22","author":"Ren","year":"2025","journal-title":"Biomed Rep"},{"key":"10.1016\/j.coi.2026.102839_bib28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102839_bib29","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.coi.2026.102839_bib30","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(23)01736-1","article-title":"Diagnosis and management of ANCA-associated vasculitis","volume":"403","author":"Kronbichler","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2026.102839_bib31","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"2","author":"Merkel","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.coi.2026.102839_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf388","article-title":"Making use of avacopan in clinical practice","volume":"19","author":"Chan","year":"2026","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.coi.2026.102839_bib33","article-title":"Advances in the treatment of antineutrophil cytoplasmic antibody associated vasculitis: current recommendations, clinical trials and real word data","volume":"136","author":"Rymarz","year":"2026","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.coi.2026.102839_bib34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00467-016-3559-2","article-title":"Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management","volume":"33","author":"Plumb","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.coi.2026.102839_bib35","doi-asserted-by":"crossref","first-page":"i164","DOI":"10.1093\/ndt\/gfu406","article-title":"Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis","volume":"30","author":"Wong","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.coi.2026.102839_bib36","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1002\/art.24876","article-title":"Classification, presentation, and initial treatment of Wegener\u2019s granulomatosis in childhood","volume":"60","author":"Cabral","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102839_bib37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/cei.13515","article-title":"The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy","volume":"202","author":"Trivioli","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coi.2026.102839_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1031445","article-title":"Role of complement activation in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis","volume":"9","author":"Kojima","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.coi.2026.102839_bib39","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2215\/CJN.19181220","article-title":"Prognostic factors and long-term outcome with ANCA-associated kidney vasculitis in childhood","volume":"16","author":"Calatroni","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.coi.2026.102839_bib40","article-title":"Clinical and renal histology findings and different responses to induction treatment affecting the long-term renal outcomes of children with ANCA-associated vasculitis: a single-center cohort analysis","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102839_bib41","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1007\/s00467-024-06406-5","article-title":"Clinicopathological characteristics of pediatric ANCA-associated glomerulonephritis","volume":"39","author":"Charnaya","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.coi.2026.102839_sbref42","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/art.43071","article-title":"Evaluating renal disease in pediatric-onset antineutrophil cytoplasmic antibody\u2013associated vasculitis: disease course, outcomes, and predictors of outcome","volume":"77","author":"Toor","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102839_bib43","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.coi.2026.102839_bib44","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.40112","article-title":"Early outcomes in children with antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"69","author":"Morishita","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102839_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-236236","article-title":"Long-term use and remission of granulomatosis with polyangiitis with the oral C5a receptor inhibitor avacopan","volume":"13","author":"Ennis","year":"2020","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.coi.2026.102839_sbref46","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf523","article-title":"Avacopan as an add-on therapy in a paediatric patient with new-onset granulomatosis with polyangiitis and acute kidney injury: a case report","volume":"65","author":"M\u00f8rk","year":"2026","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102839_sbref47","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1007\/s00467-024-06376-8","article-title":"A case of rapid avacopan-induced liver injury in pediatric granulomatosis with polyangiitis","volume":"39","author":"Nishino","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.coi.2026.102839_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14760","article-title":"Successful use of eculizumab in immediate ANCA vasculitis recurrence in a pediatric kidney transplant","volume":"28","author":"Peterson","year":"2024","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.coi.2026.102839_bib49","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1007\/s00467-023-05927-9","article-title":"Utilizing therapeutic drug monitoring to optimize therapy with eculizumab and mycophenolate mofetil in a child with C3 glomerulonephritis","volume":"38","author":"Riedl Khursigara","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.coi.2026.102839_bib50","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1007\/s00467-021-04965-5","article-title":"Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes\u2014a Pediatric Nephrology Research Consortium study","volume":"36","author":"Muff-Luett","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.coi.2026.102839_bib51","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0093-3619(08)70853-0","article-title":"Treatment of antineutrophil cytoplasmic antibody\u2013associated vasculitis: a systematic review","volume":"2008","author":"Thiers","year":"2008","journal-title":"Yearb Dermatol Dermatol Surg"},{"key":"10.1016\/j.coi.2026.102839_bib52","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2215\/CJN.0000000000000415","article-title":"Race, ethnicity, sex, gender, socioeconomic status, and representativeness of race and ethnicity in ANCA vasculitis randomized trials","volume":"19","author":"Iudici","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Supplement_1","key":"10.1016\/j.coi.2026.102839_bib53","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/rheumatology\/keaf539","article-title":"Targeting the complement system in ANCA-associated vasculitis management","volume":"65","author":"De Groot","year":"2026","journal-title":"Rheumatology"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526001160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526001160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:20:19Z","timestamp":1789089619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526001160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":53,"alternative-id":["S0952791526001160"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102839","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement inhibition in pediatric ANCA-associated vasculitis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102839"}}